Thyrocare Technologies Q4 Results 2026: Date, Revenue, PAT & Analyst Outlook

Thu Apr 09 2026

Thyrocare Technologies (NSE: THYROCARE) is preparing to announce its Q4 FY26 financial results for the period ended March 31, 2026. The board of directors is scheduled to meet on May 2026 (Expected) to approve the audited statements and consider a final dividend recommendation. With the stock at Rs 680 — against a 52-week high of Rs 900 and 1-year return of -18% — the Q4 FY26 results will be a pivotal event for investors.

Analyst estimates for Q4 FY26 revenue stand at Rs 188-208 Cr, with PAT expectations of Rs 32-40 Cr and margin projections of EBITDA 27-29%. This article covers the Thyrocare Technologies Q4 results 2026 date, earnings estimates, five key performance factors, five risks, analyst ratings, and investor FAQs.

Table of Contents

Thyrocare Technologies Q4 Results 2026 Date

Get free investment predictions and live Q4 result alerts on Univest.

Company	Results Date	Article
TCS	April 9, 2026	Preview on Univest
Infosys	April 23, 2026	Preview on Univest
Thyrocare Technologies	May 2026 (Expected)	This article

Why This Quarter Matters

Thyrocare Technologies enters Q4 FY26 with expectations of 12-16% YoY revenue growth. Q4 determines full-year FY26 performance, sets FY27 estimate baselines, and triggers final dividend announcements. At a 1-year return of -18%, this quarter’s results and FY27 guidance will be critical for determining stock trajectory.

Thyrocare Technologies Q4 FY26 Earnings Estimates

Thyrocare Technologies Q4 FY26 analyst estimates. Source: MOFSL, YES Securities, JM Financial.

Access premium SEBI-registered research on Univest.

Metric	Q3 FY26 Actual	Q4 FY26 Estimate	Driver
Revenue	Rs 167 Cr	Rs 188-208 Cr	Volume + pricing
PAT	Rs 28 Cr	Rs 32-40 Cr	Operating leverage
Margin	EBITDA 26.8%	EBITDA 27-29%	Cost control
Key Growth Metric	Q3 trend	12-16% YoY revenue growth	Management execution
Dividend Estimate	—	Rs 8-12 per share	Board recommendation

Screen Thyrocare Technologies fundamentals on Univest Screener.

5 Key Factors That Will Drive Thyrocare Technologies Q4 FY26 Performance

Revenue Momentum

Analysts expect Rs 188-208 Cr in Q4 FY26 revenue versus Rs 167 Cr in Q3. Q4 is seasonally important for the Healthcare/Diagnostics sector and the ability to convert the pipeline into recognised revenue will be the first performance test.

Margin Trajectory

Q4 FY26 margin expectations are EBITDA 27-29% versus EBITDA 26.8% in Q3. Input cost trends, employee expenses, and pricing power will determine whether the company can sustain or improve on Q3 levels.

PAT Quality

Net profit is estimated at Rs 32-40 Cr. Investors will assess whether PAT is driven by operational improvement or non-recurring items. A clean recurring profit print is most positively received by institutional investors.

Management Guidance for FY27

The most consequential output will be FY27 guidance — revenue growth bands, margin targets, and capex plans. Credible FY27 guidance carries significant weight for re-rating potential in the current macro environment.

Dividend Declaration

Thyrocare Technologies is expected to consider a final dividend of Rs 8-12 per share. The quantum signals management’s confidence in free cash flow generation and sets expectations for FY27 capital allocation.

5 Risks to Watch in Thyrocare Technologies Q4 FY26

US Tariff and Macro Headwinds

The 26% US reciprocal tariff on Indian goods has created macro uncertainty. For Thyrocare Technologies, indirect impacts include FII outflows and earnings estimate cuts if global demand slows.

Earnings Miss Risk

If Thyrocare Technologies’s Q4 FY26 results miss estimates, the stock could correct sharply. Investors should monitor revenue versus Rs 188-208 Cr and PAT versus Rs 32-40 Cr as the two primary watchpoints.

FY27 Guidance Below Consensus

If FY27 guidance falls below Street expectations, the stock may decline even if Q4 numbers are in line. Forward guidance carries more weight than the reported quarter currently.

FII Outflow Continuation

FIIs sold Rs 22,000 crore in Indian equities in a single week following the tariff announcement. Continued selling creates headwinds for Thyrocare Technologies regardless of fundamentals.

Sector Regulatory Risk

The Healthcare/Diagnostics sector faces evolving regulatory frameworks. Policy changes that increase compliance costs or alter competitive dynamics could affect Thyrocare Technologies’s profitability.

Thyrocare Technologies Share Price and Analyst Ratings

Thyrocare Technologies share price snapshot and analyst ratings. Source: Brokerages, NSE data.

Thyrocare Technologies is trading at Rs 680 as of early April 2026, against a 52-week high of Rs 900 and 52-week low of Rs 520. Market cap stands at Rs 3,600 Cr.

Brokerage	Rating	Target Price	Thesis
MOFSL	Neutral	Rs 750	PharmEasy-owned diagnostics; franchise
YES Securities	Buy	Rs 780	B2B + franchise model growing
JM Financial	Add	Rs 760	Franchise lab expansion 2,000+ target
Emkay	Neutral	Rs 720	Parent PharmEasy financial overhang

Download the Univest iOS App or Univest Android App to track Thyrocare Technologies live and receive real-time Q4 result alerts.

Conclusion

Thyrocare Technologies Q4 FY26 results on May 2026 (Expected) will be a key event for Healthcare/Diagnostics sector investors. Analysts project PAT of Rs 32-40 Cr and revenue of Rs 188-208 Cr. At Rs 680 with analyst targets from Rs 720 to Rs 750, FY27 guidance will be the most critical post-results catalyst.

For more Q4 FY26 previews, visit Univest Blogs.

Frequently Asked Questions

What is the Thyrocare Technologies Q4 results 2026 date?

The Thyrocare Technologies Q4 results 2026 date is May 2026 (Expected). The board will meet to approve audited Q4 FY26 financials and consider a final dividend recommendation.

What is the Thyrocare Technologies Q4 FY26 PAT estimate?

Analysts estimate Thyrocare Technologies Q4 FY26 PAT at Rs 32-40 Cr, based on revenue of Rs 188-208 Cr and margin of EBITDA 27-29%.

What is Thyrocare Technologies’s share price ahead of Q4 results?

Thyrocare Technologies is trading at Rs 680. The 52-week high is Rs 900 and low is Rs 520. The 1-year return is -18% and market cap is Rs 3,600 Cr.

Will Thyrocare Technologies declare a dividend in Q4 FY26?

Thyrocare Technologies is expected to consider a final dividend of Rs 8-12 per share at the Q4 FY26 board meeting on May 2026 (Expected).

Which analysts have a Buy rating on Thyrocare Technologies?

YES Securities (Buy, Rs 780), JM Financial (Add, Rs 760) have positive ratings heading into Q4 FY26.

What were Thyrocare Technologies Q3 FY26 results?

Thyrocare Technologies reported Q3 FY26 revenue of Rs 167 Cr and PAT of Rs 28 Cr, with margin at EBITDA 26.8%.

When do TCS and Infosys announce Q4 results 2026?

TCS declared Q4 FY26 results on April 9, 2026. Infosys Q4 FY26 results are scheduled for April 23, 2026. Read both previews on Univest Blogs.

Is Thyrocare Technologies a good investment ahead of Q4 results?

This depends on your risk appetite. Thyrocare Technologies has compelling long-term factors alongside genuine near-term risks. Consult a SEBI-registered financial advisor before investing.

Disclaimer: Investment in the share market is subject to risk. This article is for informational and educational purposes only. All financial data and analyst estimates are sourced from publicly available information. Verify before investing. Consult a SEBI-registered advisor before making investment decisions.